Eli Lilly is Leading the Pharmaceutical Segment, CEO Says
Dow Jones08-06
1246 ET - Eli Lilly had a strong first half of the year, CEO David Ricks says on CNBC, blowing past Wall Street estimates in the latest quarter. "It's hard to think of a time we've ever been in a better position than this," he says. "We're participating in probably the largest pharmaceutical segment ever, and we're leading it." Second quarter revenue jumped 48% to $22.97 billion on the back of continued strong demand for its GLP-1 weight-loss drugs and topped expectations for $20.69 billion. Adjusted EPS of $8.38 were also ahead of forecasts for $6.01 a share. Eli Lilly boosts its outlook for the year. Eli Lilly climbs 4%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments